Screening Siblings for Type 1 Diabetes: What Changed and Why It Matters

Type 1 diabetes runs in families. Siblings of people with Type 1 have a significantly higher risk of developing the condition than the general population. For decades, screening relatives meant a single blood test looking for autoantibodies—proteins the immune system mistakenly produces against insulin-producing cells. But a single test snapshot tells an incomplete story.

The landscape has shifted. With teplizumab now available as a treatment that can delay Type 1 onset in at-risk individuals, identifying who is at risk—and how close they are to developing diabetes—has become more actionable. This has prompted researchers and clinicians to rethink how and when siblings should be screened.

Traditionally, screening involved testing blood once for autoantibodies. If found, a person was labeled 'at risk.' But autoantibodies can persist for years without progression, or they can escalate quickly. A single measurement couldn't distinguish between these paths.

Recent research emphasizes a different approach: tracking autoantibody levels and changes over time reveals stages of disease progression. This staged view—rather than a binary 'positive or negative' result—gives families and clinicians clearer information about whether and when intervention might be beneficial. Siblings with rising or multiple autoantibodies are at higher risk of progressing to symptomatic Type 1 diabetes sooner than those with stable or lower levels.

Teplizumab is an FDA-approved treatment that delays the onset of Type 1 diabetes in people with evidence of ongoing autoimmunity. It is not a cure, but it can provide months to years before insulin becomes necessary. For this treatment to work, people must be identified before symptoms appear—which depends on effective screening and understanding of disease stages.

Knowing the stage of autoimmune progression helps families decide whether screening and monitoring make sense for them. Some siblings may have autoantibodies but progress slowly; others may progress faster. Staged information supports more personalized decision-making about further testing, monitoring frequency, and discussions with healthcare providers about prevention options.

If you have a sibling with Type 1 diabetes, discussing screening with your doctor is a reasonable first step. A single autoantibody test is a starting point, but it is no longer viewed as the final answer. If autoantibodies are found, ongoing monitoring may provide clearer insight into your personal risk trajectory.

The emergence of treatable stages means that early detection is no longer just information—it can connect to action. However, screening and any subsequent decisions should happen in consultation with your healthcare team, who can weigh your individual circumstances, family history, and preferences. Not everyone with autoantibodies will progress to Type 1 diabetes, and screening itself is a personal choice.

Source: Diabetes, obesity & metabolism. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.